Welcome to our dedicated page for Biorestorative Therapies SEC filings (Ticker: BRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioRestorative Therapies filings document the regulatory record of a Nevada regenerative medicine company listed on the Nasdaq Capital Market under BRTX. Its disclosures cover BRTX-100 clinical development for chronic lumbar disc disease, the ThermoStem metabolic program, the BioCosmeceutical platform, operating results, risk factors, and the use of capital for research, development, commercialization and working capital.
Recent filings include Form 8-K reports for financial results, Regulation FD presentations, executive compensation actions and material agreements, as well as registration statements for common stock, pre-funded warrants and common stock warrants. Proxy materials describe stockholder voting matters, charter-related proposals, board governance and compensation disclosures.
BioRestorative Therapies, Inc. files its annual report describing progress across its cell therapy pipeline and capital raising activities. The company is developing BRTX-100 for chronic lumbar disc disease, a ThermoStem metabolic program, and a commercial biocosmeceuticals line.
BRTX-100 received FDA Fast Track designation, completed enrollment of a 99-patient Phase 2 trial, and showed encouraging blinded data with over 74% of subjects achieving major functional improvement and over 72% reporting substantial pain reduction at 52 weeks without serious safety issues. The FDA also granted a Type B meeting, after which Phase 3 enabling work began.
ThermoStem gained additional patents in Europe, Israel, Japan and is advancing preclinical work using brown fat–derived stem cells. The company raised capital through warrant exercises and multiple equity offerings totaling more than $16 million in gross proceeds, but still reports no significant revenue and expects current funds may not cover planned trials and operations for the year ahead.
BioRestorative Therapies, Inc. filed an amendment to a Schedule 13G/A stating that Todd Hale Morrison beneficially owned 0 shares of the company’s common stock as of the close of business on 02/23/2026.
The filing lists 0.0% ownership and zero voting or dispositive power across all categories, and is signed by the reporting person.
BioRestorative Therapies, Inc. reports that the Reporting Persons may be deemed to beneficially own 922,143 shares of Common Stock, representing 4.1% of the class as of the close of business on 02/18/2026.
The 922,143 shares consist of 857,143 shares issuable upon exercise of one warrant ("Intracoastal Warrant 1") and 65,000 shares issuable upon exercise of a second warrant ("Intracoastal Warrant 2"). The filing states each warrant "contains a blocker provision" limiting exercises to prevent ownership above 4.99%.
Auctus Fund, LLC and related parties report a significant ownership position in BioRestorative Therapies, Inc. common stock. They disclose beneficial ownership of 895,896 shares, representing approximately 9.9% of the outstanding common stock.
This stake consists of 804,210 shares of common stock and 91,686 shares issuable upon exercise of warrants held by Auctus Fund, LLC. The percentage is calculated against 8,876,242 shares outstanding as of November 11, 2025, plus the warrant shares. Additional warrant and preferred stock conversion rights are subject to blocker provisions that prevent ownership from exceeding 9.99% of the common stock. The reporting persons state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the company.
BioRestorative Therapies, Inc. completed a public offering of 14,285,715 shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants, raising approximately $5.0 million in gross proceeds at a price of $0.35 per share or pre-funded warrant and warrant.
Each warrant is immediately exercisable at $0.35 per share and expires five years from issuance. The company plans to use the net proceeds to fund clinical trials for its BRTX-100 disc/spine program, pre-clinical work on its ThermoStem metabolic program, expand its BioCosmeceuticals platform, and for general corporate purposes and working capital.
Rodman & Renshaw LLC acted as exclusive placement agent and received a 7.0% cash fee on gross proceeds, expense reimbursement of up to $100,000, and five-year placement agent warrants for 350,000 shares at an exercise price of $0.4375 per share.
Alta Partners LLC has filed a Schedule 13G reporting a significant passive ownership position in BioRestorative Therapies, Inc. common stock. Alta Partners beneficially owns 1,787,163 shares, representing 7.7% of the company’s outstanding common stock.
Alta Partners reports sole voting and dispositive power over all 1,787,163 shares and no shared power. The filing states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of BioRestorative Therapies.
BioRestorative Therapies is conducting a primary offering of up to 14,285,715 Units at $0.35 per Unit, targeting gross proceeds of about $5 million. Each Unit includes one share of common stock (or one pre-funded warrant) plus one five-year common stock warrant exercisable at $0.35.
The company expects net proceeds of about $4.4 million after fees and expenses, to fund its Phase 2 BRTX-100 disc/spine trial, ThermoStem metabolic program, expansion of its biocosmeceutical platform, and general corporate purposes. There is no minimum offering amount, no escrow, and sales are on a reasonable best efforts basis through Rodman & Renshaw.
Shares outstanding were 9,046,242 as of February 11, 2026, and could rise to up to 23,331,957 if the maximum number of Units is sold, assuming no pre-funded warrants are issued and no warrants are exercised. The prospectus highlights a large accumulated deficit, ongoing losses, and substantial doubt about the company’s ability to continue as a going concern without additional financing.
BioRestorative Therapies, Inc. filed Amendment No. 1 to its Form S-1 registration statement as an exhibit-only update. The amendment adds a Form of Placement Agency Agreement, identified as Exhibit 10.51, and replaces the prior Filing Fee Table with a corrected version, filed as Exhibit 107.
The company states that the prospectus and the remaining portions of Part II of the original registration statement are unchanged and therefore omitted from this amendment. The filing is signed by President and Chief Executive Officer Lance Alstodt and other officers and directors, confirming authorization of this technical update to the pending registration.
BioRestorative Therapies is registering up to 9,708,738 Units, each with one share of common stock (or one pre-funded warrant) and one common stock warrant, for an assumed public offering price of $1.03 per Unit, implying approximately $10,000,000 in gross proceeds and about $9.0 million in estimated net proceeds.
Shares of common stock outstanding were 8,876,242 as of February 4, 2026, rising to up to 18,584,980 shares if the maximum number of Units is sold, excluding warrant and option exercises and other convertible securities. The common stock and pre-funded warrants are paired with five-year warrants and feature 4.99% or 9.99% beneficial ownership caps.
The company develops cell-based therapies for disc/spine disease (BRTX-100), metabolic disorders (ThermoStem) and operates a biocosmeceutical platform. It is a smaller reporting company with an accumulated deficit of $166,713,054 as of September 30, 2025, recurring losses, negative operating cash flows and disclosed substantial doubt about its ability to continue as a going concern.
BioRestorative Therapies, Inc. is registering up to 508,592 shares of common stock for resale by existing securityholders. These shares are issuable upon exercise of outstanding warrants and may be sold over time on the Nasdaq Capital Market or in private transactions at market, fixed, or negotiated prices.
The company reports 8,876,242 shares of common stock outstanding as of November 17, 2025. BioRestorative will not receive any proceeds from the resale of shares by the selling securityholders, but would receive up to $1,398,628 in gross proceeds if all related warrants are exercised at the $2.75 per share exercise price. The prospectus highlights that an investment in the stock involves a high degree of risk and that the most recent audited financial statements include an auditor’s explanatory paragraph about the company’s ability to continue as a going concern.